文献速递MDS 与骨髓增殖性肿瘤

初诊时血红蛋白浓度升高的原发性骨髓纤维化

Primary myelofibrosis with increased haemoglobin concentration at presentation.
PubMed 文献 · Br J Haematol · 2025-06-23

在帕维亚-CSM数据库中963例连续登记的原发性骨髓纤维化(PMF)患者中,100例初诊时血红蛋白浓度升高(女性≥160 g/L或男性≥165 g/L)。这些患者更多为女性且更年轻,白细胞和血小板计数更高,JAK2V617F及等位基因负荷更高,但疾病活动度更低、炎症更轻,生存期更长(22年 vs 15年;p < 0.001)。

要点

  • 初诊血红蛋白升高的PMF患者多为女性、年轻,JAK2V617F阳性率及VAF更高。
  • 该类患者脾脏更小、乳酸脱氢酶更低、骨髓纤维化更轻、炎症更轻。
  • 该类患者更易演变为白细胞增多,进展为骨髓衰竭表型的风险更低,生存期更长(22 vs 15年;p < 0.001)。

核心结论

  • 初诊血红蛋白升高的PMF是JAK2V617F驱动的过度增殖伴炎症较轻的独特变异型,这些特征影响预后和治疗。

研究设计与样本

  • 回顾性队列研究,基于帕维亚-CSM数据库963例连续登记的原发性骨髓纤维化患者,其中100例初诊时血红蛋白浓度升高(女性≥160 g/L或男性≥165 g/L)。

主要发现

  • 血红蛋白升高组相比无升高组更常为女性且更年轻,白细胞和血小板浓度更高,JAK2V617F阳性率及VAF更高。
  • 血红蛋白升高组脾脏更小、血浆乳酸脱氢酶更低、血CD34阳性细胞浓度更低、骨髓纤维化更轻、血浆高敏C反应蛋白更低。
  • 血红蛋白升高组更易演变为白细胞浓度升高,进展为骨髓衰竭表型的风险更低,生存期更长(22年 vs 15年;p < 0.001)。
  • 在血红蛋白升高组中,年龄>50岁和JAK2V617F VAF>75%与更差生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia-CSM database had haemoglobin concentration at diagnosis ≥160 g/L in females or ≥ 165 g/L in males. These subjects were more often female and younger; had higher white blood cell (WBC) and platelet concentrations; and higher frequency of JAK2V617F and JAK2V617F variant allele frequency (VAF) compared with those without increased haemoglobin at diagnosis. They had less active disease defined as smaller spleen, lower plasma lactate dehydrogenase, lower blood CD34-positive cell concentration and less bone marrow fibrosis. They also had a lower plasma high-sensitivity C-reactive protein concentration consistent with less inflammation. These subjects were more likely to evolve towards an increased WBC concentration and had a lower risk of progressing to a myelodepletive phenotype compared with those without increased haemoglobin concentration at diagnosis and longer survival (22 vs. 15 years; p < 0.001). In subjects with increased haemoglobin concentration at diagnosis, age >50 years and JAK2V617F VAF > 75% correlated with worse survival. Our findings suggest that PMF with increased haemoglobin concentration at diagnosis is a unique variant characterized by JAK2V617F-driven hyperproliferation with less inflammation. These features impact prognosis and therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Barosi G, Campanelli R, Catarsi P, et al. Primary myelofibrosis with increased haemoglobin concentration at presentation. Br J Haematol. 2025. PMID: 40551505. doi:10.1111/bjh.20233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。